ATSENA THERAPEUTICS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2019-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.atsenatx.com
ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis
- First Posted Date
- 2023-05-26
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- Atsena Therapeutics Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT05878860
- Locations
- 🇺🇸
Children's Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸Bascom Palmer Eye Institute, Miami, Florida, United States
🇺🇸Oregon Health Sciences University, Portland, Oregon, United States
Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D
Phase 1
Active, not recruiting
- Conditions
- LCALCA1Leber Congenital Amaurosis
- Interventions
- Drug: Triamcinalone AcetonideDrug: Trimethoprim/polymyxin B
- First Posted Date
- 2019-04-18
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Atsena Therapeutics Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT03920007
- Locations
- 🇺🇸
Casey Eye Institute - Oregon Health & Science University, Portland, Oregon, United States
🇺🇸Scheie Eye Institute, University of Pennsylvania, Philadelphia, Pennsylvania, United States
© Copyright 2025. All Rights Reserved by MedPath